Health-related quality-of-life in treatment-naive CLL/SLL patients treated with zanubrutinib versus bendamustine plus rituximabPaolo Ghia, Mazyar Shadman, Gisoo Barnes et al.|Current Medical Research and Opinion|2023Cited by 3
Zanubrutinib for the treatment of patients with del(17p) and/or <i>TP53</i> CLL/SLL: analysis across clinical studiesConstantine S. Tam, Jennifer R. Brown, Ian W. Flinn et al.|Blood Advances|2025Cited by 2